Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Blood (2017) 130 (Supplement 1): 725.

https://doi.org/10.1182/blood.V130.Suppl_1.725.725

Published: 2017

Journal Articles

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Blood (2017) 130 (Supplement 1): 1631.

https://doi.org/10.1182/blood.V130.Suppl_1.1631.1631

Published: 2017

Journal Articles

Results from a Phase 1b (OX1222) Dose-Ranging Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Justin M Watts, MD, Ronan T. Swords, MD PhD FRCPI, FRCPath, Christopher R. Cogle, MD, Gary J. Schiller, MD, Tara L. Lin, MD

Blood (2017) 130 (Supplement 1): 2644.

https://doi.org/10.1182/blood.V130.Suppl_1.2644.2644

Published: 2017

Journal Articles

Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients

Terrence J Bradley, MD, Jorge Monge, MD, Chetasi Talati, MD, Sandra Dannielle Algaze, MD BS, Christine Angela Vaupel, PhD, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Jeff Hall, Jeffrey E. Lancet, MD, Eric Padron, MD, Ronan T. Swords, MD PhD FRCPI, FRCPath, Justin M Watts, MD

Blood (2017) 130 (Supplement 1): 2699.

https://doi.org/10.1182/blood.V130.Suppl_1.2699.2699

Published: 2017

Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 98.

https://doi.org/10.1182/blood.V128.22.98.98

Published: 2016

Journal Articles

Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology

Yamina Lilliana Carattini, MCLS, Terrence Bradley, MD, Fernando Vargas, MD, Justin M Watts, MD, Jennifer R Chapman, MD, German Campuzano-Zuluaga, MD, Francisco Vega, MD PhD, Deukwoo Kwon, PhD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2016) 128 (22): 5527.

https://doi.org/10.1182/blood.V128.22.5527.5527

Published: 2016

Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 343.

https://doi.org/10.1182/blood.V128.22.343.343

Published: 2016

Journal Articles

The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA)

Justin M Watts, MD, Aymee Perez, PhD, Fernando Vargas, MD, Yao-Shan Fan, MD PhD, Alejandra Weisman, Ana Rodriguez, Omar Lopez, Francisco Vega, MD PhD, Ronan T Swords, MD PhD FRCPI, FRCPath, Arthur Zelent, PhD

Blood (2016) 128 (22): 1526.

https://doi.org/10.1182/blood.V128.22.1526.1526

Published: 2016

Journal Articles

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Blood (2016) 128 (22): 1070.

https://doi.org/10.1182/blood.V128.22.1070.1070

Published: 2016

Journal Articles

Mutational Frequency in Hispanic Vs. Non-Hispanic Patients with Acute Myeloid Leukemia (AML)

Jorge Monge, MD, Christine Vaupel, PhD, Ronan T Swords, MD PhD FRCPI, FRCPath, Terrence Bradley, MD, Ryan Chapman, DO, Naiomi Gunaratne, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Eric Padron, MD, Fernando Vargas, MD, Jeff Hall, PhD, Justin M Watts, MD

Blood (2016) 128 (22): 2796.

https://doi.org/10.1182/blood.V128.22.2796.2796

Published: 2016

Journal Articles

A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Justin M. Watts, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Christopher R. Cogle, MD, Tara L. Lin

Blood (2016) 128 (22): 4037.

https://doi.org/10.1182/blood.V128.22.4037.4037

Published: 2016

Journal Articles

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

Diana M Byrnes, MD MPH, Christopher R Dermarkarian, BS, Ryan Kahn, BA, MHS, Deukwoo Kwon, PhD, Fernando Vargas, MD, Judith Hurley, MD, Justin M. Watts, MD, Jonathan H. Schatz, MD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2016) 128 (22): 5973.

https://doi.org/10.1182/blood.V128.22.5973.5973

Published: 2016

Journal Articles

Sodium Salicylate Has a Priming Effect When Combined with Azacitidine in Pre-Clinical Models of AML

Yehuda E. Deutsch, MD, Aymee Perez, PhD, Ana Rodrigues, BS, Ezra S. Blumenthal, Elena Cubedo, PhD, Justin M. Watts, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Arthur Zelent, PhD

Blood (2014) 124 (21): 2300.

https://doi.org/10.1182/blood.V124.21.2300.2300

Published: 2014

Journal Articles

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

Ronan T Swords, MD PhD FRCPI, FRCPath, Michael R Savona, MD, Michael B Maris, MD, Harry P Erba, MD PhD, Jesus G. Berdeja, MD, James M. Foran, MD, Zhaowei Hua, PhD, Hélène M Faessel, PharmD, PhD, Ajeeta B Dash, PhD, Farhad Sedarati, PhD, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2014) 124 (21): 2313.

https://doi.org/10.1182/blood.V124.21.2313.2313

Published: 2014

Journal Articles

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Ronan T Swords, MD PhD FRCPI, FRCPath, Andrew H Wei, MBBS, PhD, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPat, Anjali S. Advani, MD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Ian D Lewis, MBBS, PhD, Peter L. Greenberg, MD PhD, Jorge E. Cortes, MD, Geoff T Yarranton, PhD, Jackie M. Walling, MBChB, PhD, Jeffrey E. Lancet, MD

Blood (2014) 124 (21): 3756.

https://doi.org/10.1182/blood.V124.21.3756.3756

Published: 2014

Journal Articles

Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?

Yehuda E. Deutsch, MD, German Campuzano-Zuluaga, MD, Matthew P Salzberg, Alexandra Gomez Arteaga, MD, Justin M. Watts, MD, Jennifer R Chapman, MD, Offiong F Ikpatt, MD, Francisco Vega, MD PhD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2014) 124 (21): 1004.

https://doi.org/10.1182/blood.V124.21.1004.1004

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Blood (2014) 124 (21): 115.

https://doi.org/10.1182/blood.V124.21.115.115

Published: 2014

Journal Articles

The NEDD8 Conjugation Pathway Inhibitor MLN4924 Activates AMPK and Induces The ER Stress/UPR-Mediated Cell Death Pathway In Acute Lymphoblastic Leukemia

Gilles M. Leclerc, Ph.D., Shuhua Zheng, B.Sc., Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Guy J. Leclerc, Ph.D., Julio C. Barredo, M.D.

Blood (2013) 122 (21): 1285.

https://doi.org/10.1182/blood.V122.21.1285.1285

Published: 2013

Journal Articles

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

Daniel J. DeAngelo, MD, Ph.D, Harry P Erba, MD, Michael B Maris, MD, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Faiz Anwer, MD, Jessica K Altman, MD, Zhaowei Hua, Ph.D, Stephen J Blakemore, Ph.D, Hélène Faessel, Ph.D, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2013) 122 (21): 1443.

https://doi.org/10.1182/blood.V122.21.1443.1443

Published: 2013

Journal Articles

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Jeffrey E Lancet, MD, Andrew H Wei, MBBS, PhD, Simon TS Durrant, Mark S. Hertzberg, MBBS, PhD, FRACP, FRCPA, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Ian D Lewis, MB, BS, PhD, Brian Jonas, MD, PhD, Jorge E. Cortes, MD, Geoffrey Yarranton, PhD, Jackie M. Walling, MBChB, PhD

Blood (2013) 122 (21): 3838.

https://doi.org/10.1182/blood.V122.21.3838.3838

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Results from a Phase 1b (OX1222) Dose-Ranging Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA)

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Mutational Frequency in Hispanic Vs. Non-Hispanic Patients with Acute Myeloid Leukemia (AML)

A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

Sodium Salicylate Has a Priming Effect When Combined with Azacitidine in Pre-Clinical Models of AML

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

The NEDD8 Conjugation Pathway Inhibitor MLN4924 Activates AMPK and Induces The ER Stress/UPR-Mediated Cell Death Pathway In Acute Lymphoblastic Leukemia

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only